Nexus stent graft demonstrates promising mid | 合法醫療器材資訊網

2019年11月5日—Theoff-the-shelfNexussystemisthefirstCEmark–approvedbranchedstentgraftfortheaorticarch.Designfeaturesthatassistinminimizing ...

Positive two-year results from a prospective multicentre premarket study including 25 patients treated with the Nexus aortic arch stent graft (Endospan) were presented today at the 2019 Vascular Interventional Advances conference (VIVA) in Las Vegas, USA (4–7 November).

Technical success was achieved for all intended Nexus introductions and deployments (100%). At 30 days, two (8%) patients died from cardiac causes and two (8%) patients showed non-disabling stroke, which resolved completely within 30 days.

During a mean follow-up of 25 months, there was one additional procedure-related mortality from stroke, and one patient was converted to open surgery following retrograde type A dissection. During follow-up, aneurysm size decreased or remained stable in 96% of the patients, with no aneurysm-related deaths.

All pati...